(P 064) A SYSTEMATIC REVIEW OF PATIENT-REPORTED OUTCOMES USED TO MEASURE HEALTH-RELATED QUALITY OF LIFE IN SOFT-TISSUE SARCOMA

Objective: FDA defines Patient-reported Outcomes (PRO) as measurement that are based on a report that comes directly from the patient (i.e., study subject) about the status of a patient’s health condition without amendment or interpretation of the patient’s response by a clinician or anyone else. Health-related quality of life (HRQOL) is defined an individual’s perception of the effects of illness or treatment on various aspects of his life. HRQOL is a multi-dimensional construct and quantified using PROs. PROs provide direct information as it relates to the patient’s perspective of their health. Soft-tissue sarcomas (STS) are heterogenous group that arise from connective tissues such as muscle and fat. STS are rare cancers and typically affects young population in the productive years of their life.
There is limited information related to what PROs are used to measure HRQOL in people with STS. The purpose of this study is to systematically review recent literature on PROs used STS from active care through survivorship.

Methods: We have systematically reviewed the literature between 2015 and 2018 and included all articles that were published in English-language where any PROs were reported in studies with STS.

Results: An integrated research methodology was be used to summarize the PROs used STS. A total of seven studies: two cross-sectional surveys, one systematic review, one expert review, one cohort study and two qualitative studies were obtained were included in this review. Beside functional restoration, there were three areas of importance to extremity STS patients: symptom management, the experienced distress under the course of diagnosis and treatment and emotional restoration. Fourteen PRO measures were used across the included studies, although none of them was specified to Extremity STS patients.

Conclusion: There is a compelling need to further QOL-related research, specifically in patients with extremity soft-tissue sarcoma, Using existing PROs and patient’s areas of importance to develop STS-specific QOL measure.